DIA AI Consortium: Drug Discovery, Development, and Commercialization

The DIA Artificial Intelligence Consortium is a global, multi-stakeholder initiative uniting regulators, industry, academia, and technology innovators to tackle the practical challenges of AI in drug development.

Organized into three working groups

1. Use Case Classification,

2. Model Validation & Valuation, and

3. Regulatory Frameworks & Terminology Alignment—

The consortium develops actionable frameworks, tools, and guidance.

In its first year, the consortium is focused on:

• Defining a structured AI Use Case Classification Framework

• Creating practical Model Validation & Valuation guidance to help stakeholders evaluate the quality, reliability, and fitness-for-purpose of AI/ML systems

• Harmonizing regulatory terminology and frameworks to support cross-jurisdictional alignment

These efforts establish the methodology and resources that underpin responsible AI adoption, providing practical guidance across discovery, development, and commercialization.